Earnings Summary

Magenta Therapeutics Inc’s net profit jumped 80.99% since last year same period to $-3.28Mn in the Q2 2023. On a quarterly growth basis, Magenta Therapeutics Inc has generated 87.47% jump in its net profits since last 3-months.

Magenta Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.28 - a 6.67% jump from last quarter’s estimates.

Magenta Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.28.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Magenta Therapeutics Inc’s return on assets (ROA) stands at -0.29.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Magenta Therapeutics Inc’s return on equity (ROE) stands at -0.65.